 | | Vol. 15.42 – 27 October, 2021 |
| |
|
|
| The authors presented a chip-based culture system that enabled self-organization of micropatterned stem cells into precise 3D cell-fate patterns and organ shapes and used this system to recreate neural tube folding from human stem cells in a dish.
[Nature] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported the development of a cerebral organoid slice model derived from human induced pluripotent stem cells that recapitulated mature cortical architecture and displayed early molecular pathology of C9ORF72 amyotrophic lateral sclerosis overlapping with frontotemporal dementia (ALS/FTD).
[Nature Neuroscience] |
|
|
|
| In brains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals and animal models, scientists found an increased number of empty basement membrane tubes, so-called string vessels that represented remnants of lost capillaries.
[Nature Neuroscience] |
|
|
|
| Neural-stem cells were isolated from parthenogenetic lizard embryos, rendered unresponsive to Hedgehog signaling via CRISPR/Cas9 gene knockout of smoothened, and implanted back into clonally-identical adults that regulated tail regeneration.
[Nature Communications] |
|
|
|
| Investigators developed a strategy that compared the epigenetic and transcriptional make-up of primary glioblastoma cells with patient-matched expanded potential stem cell (EPSC)-derived neural stem cells.
[Nature Communications] |
|
|
|
| The authors isolated patient-derived glioblastoma cells that showed high GD2 antigen expression which represented a potential target for chimeric antigen receptor (CAR) T strategy.
[npj Precision Oncology] |
|
|
|
| Researchers presented the role of the actin-regulating protein cofilin1 in regulating mitochondrial pathways in oxidative neuronal death.
[Cell Death & Disease] |
|
|
|
| Scientists found that RAN binding protein 10 (RANBP10) was overexpressed in glioblastoma (GBM), and high RANBP10 expression was closely linked to poor survival of patients with GBM.
[Cell Death & Disease] |
|
|
|
| Investigators found that pyrvinium pamoate (PP) and temozolomide (TMZ) had synergistic effect on inhibiting the viability of glioblastoma multiforme (GBM) cells, and PP induced inhibition of MGMT and enhanced the TMZ chemosensitivity of GBM cells through down-regulating Wnt/β-catenin pathway.
[Cell Death Discovery] |
|
|
|
| With various stimulus, chances for neural stem cells (NSCs) to differentiate into neurons, astrocytes, oligodendrocytes are great and is considered as a potential source of stem cell therapy to spinal cord injury (SCI). The authors used adeno-associated virus to carry the target gene to transfect NSCs.
[Cell Death Discovery] |
|
|
|
| Researchers investigated the impact of individual drugs sulfasalazine (SAS) and dihydroartemisinin (DHA), their 1:1 combination, and a novel SAS-DHA hybrid compound on rodent and human glioma cells.
[Scientific Reports] |
|
|
|
| Investigators demonstrated the generation of mucopolysaccharidosis type IIIA (MPS IIIA) induced pluripotent stem cells, and neural progenitor cells, the latter of which displayed reduced proliferation and neurogenic capacity.
[Molecular Genetics and Metabolism Reports] |
|
|
|
|
| The authors provide an update on alcohol research, focusing on multiple levels of alcohol-induced adaptations, from intracellular changes to changes in neural circuits.
[Trends in Neurosciences] |
|
|
|
| Scientists discuss dynamic and non-overlapping spatiotemporal protein-level programs and their potentially essential role for unraveling critical secreted paracrine signals or neurodevelopmental proteins requiring post-translational modification for biological activity.
[Molecular Psychiatry] |
|
|
|
|
| Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder and schizophrenia.
[Boehringer Ingelheim] |
|
|
|
| BioVie, Inc. announced that the FDA has authorized the company to initiate a Phase II study assessing NE3107’s potential pro-motoric impact in Parkinson’s disease (PD) patients. The NM201 study is a double-blind, placebo-controlled and pharmacokinetics study in PD participants treated with carbidopa/levodopa and NE3107.
[BioVie, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| November 8 – 10, 2021
Virtual |
|
|
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Calgary – Calgary, Alberta, Canada |
|
|
|
| | Flanders Institute for Biotechnology – Leuven, Belgium |
|
|
|
| | Center for Molecular and Behavioral Neuroscience – Newark, New Jersey, United States |
|
|
|
|
| Brigham and Women’s Hospital – Boston, Massachusetts, United States |
| | |  | |  | | |  | |
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
